Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18865727 | N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGS | November 2024 | April 2025 | Allow | 5 | 0 | 0 | No | No |
| 18883472 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | September 2024 | November 2024 | Allow | 2 | 0 | 0 | No | No |
| 18742840 | CRYSTALLINE FORMS OF COMPOSITIONS COMPRISING PSILOCIN AND PSILOCYBIN | June 2024 | June 2025 | Allow | 12 | 1 | 0 | No | No |
| 18717094 | PSILOCYBIN DERIVATIVES | June 2024 | April 2025 | Allow | 10 | 1 | 0 | No | No |
| 18680473 | METHODS OF TREATING MOOD DISORDERS | May 2024 | December 2024 | Allow | 6 | 1 | 0 | No | No |
| 18624982 | POLYMORPHIC COMPOUNDS AND USES THEREOF | April 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18621997 | SILICON CONTAINING DETECTABLE COMPOUNDS AND USES THEREOF | March 2024 | February 2025 | Allow | 11 | 1 | 0 | No | No |
| 18621972 | POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18604747 | ORGANIC COMPOUND SALTS | March 2024 | May 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18600018 | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE | March 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18438838 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18418560 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | January 2024 | October 2024 | Allow | 8 | 0 | 0 | No | No |
| 18414958 | CRYSTAL FORMS OF IMMUNOMODULATORS | January 2024 | November 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18542220 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | December 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18534253 | MALASSEZIN AND ANALOGS THEREOF AS SKIN BRIGHTENING AGENTS | December 2023 | May 2025 | Allow | 17 | 1 | 0 | No | No |
| 18532752 | OXYSTEROLS AND METHODS OF USE THEREOF | December 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18517432 | METHODS OF TREATING MUTANT LYMPHOMAS | November 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18500247 | PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE) | November 2023 | November 2024 | Allow | 13 | 1 | 0 | No | No |
| 18384815 | 4,5-BIS(4-BROMOPHENYL)-1-HEXYL-2-(4-HYDROXY-3-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18495288 | 4-(4,5-BIS(4-BROMOPHENYL)-2-(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18493231 | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE | October 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18484211 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | October 2023 | June 2024 | Abandon | 8 | 1 | 0 | No | No |
| 18469032 | Carbamoyl Phenylalaninol Compounds and Uses Thereof | September 2023 | November 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18467022 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | September 2023 | September 2024 | Allow | 13 | 1 | 0 | No | No |
| 18462355 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | September 2023 | February 2024 | Allow | 6 | 1 | 0 | No | No |
| 18453431 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | August 2023 | October 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18234629 | SYNTHESIS METHOD FOR N-METHYL-3-SUBSTITUTED METHYL-4-PYRAZOLAMIDE DERIVATIVE AND N-METHYL-3-SUBSTITUTED METHYL-4-PYRAZOLIC ACID | August 2023 | August 2024 | Allow | 12 | 3 | 0 | No | No |
| 18233160 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | August 2023 | November 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18227325 | N-AROMATIC AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | July 2023 | March 2025 | Allow | 20 | 2 | 0 | No | No |
| 18218216 | C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | July 2023 | May 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18327990 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | June 2023 | March 2025 | Allow | 22 | 2 | 0 | No | No |
| 18204870 | CRYSTALLINE FORMS OF COMPOSITIONS COMPRISING PSILOCIN AND PSILOCYBIN | June 2023 | March 2024 | Allow | 9 | 1 | 0 | No | No |
| 18197414 | CRYSTALLINE FORMS OF 3-SUBSTITUTED 1,2,4- OXADIAZOLE | May 2023 | August 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18317169 | CRYSTALLINE BIS-MIPROCIN FUMARATE | May 2023 | April 2024 | Allow | 11 | 1 | 0 | No | No |
| 18313040 | SMARCA DEGRADERS AND USES THEREOF | May 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18142662 | PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF | May 2023 | June 2025 | Allow | 25 | 3 | 0 | No | No |
| 18141844 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | May 2023 | October 2024 | Abandon | 18 | 3 | 0 | No | No |
| 18129725 | CRYSTALLINE SALT FORMS OF MESEMBRINE | March 2023 | January 2024 | Allow | 10 | 1 | 1 | No | No |
| 18179622 | Compounds Useful for Treating Liver Diseases | March 2023 | December 2024 | Allow | 21 | 0 | 1 | No | No |
| 18115942 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | March 2023 | September 2024 | Abandon | 19 | 2 | 0 | No | No |
| 18173717 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | February 2023 | July 2023 | Allow | 5 | 1 | 0 | No | No |
| 18172691 | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE | February 2023 | September 2023 | Allow | 7 | 1 | 0 | No | No |
| 18170022 | HETEROCYCLIC COMPOUND | February 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18166934 | INTERMEDIATE COMPOUNDS AND METHODS | February 2023 | August 2024 | Allow | 18 | 2 | 0 | No | No |
| 18163388 | DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | February 2023 | November 2024 | Allow | 22 | 2 | 0 | No | No |
| 18162375 | PLATINUM COMPOUNDS THAT INHIBIT CONSTITUTIVE STAT3 SIGNALING AND INDUCE CELL CYCLE ARREST AND APOPTOSIS OF MALIGNANT CELLS | January 2023 | January 2024 | Abandon | 12 | 1 | 0 | No | No |
| 18101387 | CRYSTAL FORMS OF IMMUNOMODULATORS | January 2023 | November 2023 | Allow | 9 | 1 | 0 | No | No |
| 18088692 | USE OF COLCHICINE TO INHIBIT TUMOR GROWTH AND METASTASES | December 2022 | September 2023 | Allow | 9 | 1 | 0 | No | No |
| 18087672 | Treatment of Respiratory Diseases | December 2022 | January 2024 | Allow | 13 | 2 | 0 | No | No |
| 18062469 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | December 2022 | September 2023 | Allow | 10 | 1 | 0 | No | No |
| 17999931 | NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION | November 2022 | August 2023 | Allow | 8 | 1 | 0 | No | No |
| 18058587 | PRODRUGS OF 4- ( (1R, 3S) -6-CHLORO-3-PHENYL-2, 3-DIHYDRO-1H-INDEN-1-YL) -1,2, 2-TRIMETHYLPIPERAZINE AND 4- ( (1R, 3S)-6-CHLORO-3- (PHENYL-D5) -2, 3-DIHYDRO-1H-INDEN-1-YL) -2, 2-DIMETHYL-1 (METHYL-D3) PIPERAZINE | November 2022 | April 2024 | Allow | 17 | 2 | 0 | No | No |
| 17993389 | ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES AND USES THEREOF | November 2022 | January 2024 | Abandon | 14 | 1 | 0 | No | No |
| 17991875 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | November 2022 | June 2023 | Allow | 7 | 0 | 0 | No | No |
| 17992284 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | November 2022 | December 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 17999310 | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE | November 2022 | December 2024 | Allow | 25 | 2 | 0 | No | No |
| 17982451 | ANALOGS OF N,N,N-TRIMETHYL-4-PHOSPHORYLOXYTRYPTAMINE | November 2022 | August 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18051145 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | October 2022 | October 2023 | Allow | 12 | 1 | 0 | No | No |
| 17977398 | BENZYLTRYPTAMINE COMPOUNDS | October 2022 | January 2024 | Allow | 15 | 3 | 0 | Yes | No |
| 18050211 | METABOLITES OF [3-(4-(2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4 YL)-PHENOXY)-PROPYL]-DIETHYL-AMINE | October 2022 | February 2024 | Allow | 16 | 2 | 0 | No | No |
| 17965914 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | October 2022 | November 2023 | Allow | 13 | 1 | 0 | No | No |
| 18046471 | Synthetic Sphingolipid-Like Molecules, Drugs, Methods of Their Synthesis and Methods of Treatment | October 2022 | January 2024 | Allow | 15 | 2 | 0 | No | No |
| 18045584 | PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE) | October 2022 | August 2023 | Allow | 10 | 1 | 0 | No | No |
| 17963576 | COMPOUNDS AND USES THEREOF | October 2022 | November 2023 | Abandon | 13 | 1 | 0 | No | No |
| 17938835 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | October 2022 | March 2023 | Allow | 5 | 1 | 0 | No | No |
| 17937283 | SYNTHESIS OF NIROGACESTAT | September 2022 | January 2025 | Allow | 28 | 5 | 1 | Yes | No |
| 17995180 | CRYSTALLINE FORM OF OZANIMOD HYDROCHLORIDE | September 2022 | May 2025 | Allow | 31 | 0 | 0 | No | No |
| 17935256 | PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | September 2022 | February 2023 | Allow | 5 | 1 | 0 | No | No |
| 17951594 | ALDEHYDE AND KETONE DERIVATIVES OF PSILOCYBIN AND METHODS OF USING | September 2022 | September 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 17947287 | Salts of Nintedanib and Crystalline Forms Thereof | September 2022 | November 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17946457 | AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | September 2022 | August 2023 | Allow | 11 | 1 | 0 | No | No |
| 17942706 | CRYSTALLINE FORMS OF COMPOSITIONS COMPRISING PSILOCIN AND PSILOCYBIN | September 2022 | April 2023 | Allow | 7 | 1 | 0 | No | No |
| 17941425 | GLYCOSYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | September 2022 | October 2023 | Allow | 13 | 2 | 1 | No | No |
| 17903103 | HYDROXYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | September 2022 | August 2024 | Allow | 24 | 4 | 1 | No | No |
| 17897961 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | August 2022 | January 2024 | Allow | 17 | 2 | 0 | No | No |
| 17801552 | CRYSTALLINE BIS-MIPROCIN FUMARATE | August 2022 | February 2023 | Allow | 6 | 0 | 0 | Yes | No |
| 17887109 | ISOTOPICALLY LABELED TRYPTAMINES AND ANALOGS THEREOF | August 2022 | January 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17885978 | C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | August 2022 | May 2023 | Allow | 9 | 2 | 0 | Yes | No |
| 17882448 | SILICON CONTAINING DETECTABLE COMPOUNDS AND USES THEREOF | August 2022 | January 2024 | Allow | 17 | 2 | 0 | No | No |
| 17881340 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF | August 2022 | November 2024 | Allow | 27 | 3 | 0 | No | No |
| 17864198 | 1,5-DISUBSTITUTED 1,2,3-TRIAZOLES ARE INHIBITORS OF RAC/CDC42 GTPASES | July 2022 | November 2023 | Allow | 16 | 2 | 0 | No | No |
| 17860816 | OXYSTEROLS AND METHODS OF USE THEREOF | July 2022 | September 2023 | Allow | 15 | 1 | 0 | No | No |
| 17851882 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | June 2022 | April 2024 | Allow | 22 | 2 | 0 | No | No |
| 17848156 | NOVEL COMPOUNDS | June 2022 | October 2023 | Allow | 16 | 2 | 0 | No | No |
| 17847811 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | June 2022 | June 2023 | Allow | 12 | 1 | 0 | No | No |
| 17842367 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | June 2022 | June 2023 | Allow | 12 | 1 | 0 | No | No |
| 17806905 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | June 2022 | May 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17835098 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | June 2022 | October 2023 | Allow | 16 | 1 | 0 | No | No |
| 17780125 | HETEROCYCLIC COMPOUND | May 2022 | June 2025 | Allow | 37 | 1 | 0 | No | No |
| 17777506 | Fluorescent acridinium salts, synthesis thereof and use for detection of cardiolipin | May 2022 | April 2025 | Allow | 35 | 1 | 0 | No | No |
| 17737899 | SILICON CONTAINING DETECTABLE COMPOUNDS AND USES THEREOF | May 2022 | July 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17730528 | SYNTHESIS AND APPLICATION OF FLUORESCENT DYE WITH PHENANTHRIDINE AND BENZOTHIAZOLE CONJUGATED | April 2022 | January 2024 | Allow | 21 | 2 | 0 | No | No |
| 17660981 | PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | April 2022 | August 2022 | Allow | 4 | 1 | 0 | No | No |
| 17718760 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | April 2022 | June 2023 | Allow | 14 | 1 | 0 | No | No |
| 17717952 | COMPOSITIONS AND METHODS COMPRISING RESVERATROL | April 2022 | April 2023 | Allow | 12 | 1 | 0 | No | No |
| 17766662 | AN INDUSTRIAL SCALE PROCESS FOR THE PREPARATION OF PROTHIOCONAZOLE | April 2022 | June 2025 | Allow | 38 | 1 | 0 | No | No |
| 17708264 | PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF | March 2022 | March 2023 | Allow | 11 | 1 | 0 | No | No |
| 17694353 | METHODS AND SYSTEMS FOR SENSITIVE AND MULTIPLEXED ANALYSIS OF BIOLOGICAL SAMPLES USING HIGH-PERFORMANCE CLEAVABLE, DETECTABLY-LABELED TYRAMIDE | March 2022 | March 2025 | Allow | 36 | 3 | 1 | No | No |
| 17641989 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | March 2022 | March 2025 | Allow | 36 | 0 | 0 | No | No |
| 17680411 | DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | February 2022 | January 2023 | Allow | 11 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JACKSON, SHAWQUIA.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 46.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner JACKSON, SHAWQUIA works in Art Unit 1626 and has examined 1,946 patent applications in our dataset. With an allowance rate of 80.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 23 months.
Examiner JACKSON, SHAWQUIA's allowance rate of 80.0% places them in the 42% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by JACKSON, SHAWQUIA receive 1.50 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by JACKSON, SHAWQUIA is 23 months. This places the examiner in the 74% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -4.9% benefit to allowance rate for applications examined by JACKSON, SHAWQUIA. This interview benefit is in the 3% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 37.6% of applications are subsequently allowed. This success rate is in the 83% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 73.2% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 84% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 88.6% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 92.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 64.9% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 5.2% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.6% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.